Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03135275
Other study ID # MULTISTARS_USZ
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2016
Est. completion date May 2023

Study information

Verified date January 2024
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the trial is to compare, in patients presenting with ST segment elevation myocardial infarction (STEMI) and multi-vessel disease (MVD), the safety and efficacy of immediate complete revascularization of all significant coronary lesions versus culprit vessel only revascularization and staged percutaneous coronary intervention (PCI) of all significant coronary lesions (within 19 to 45 days), in a non-inferiority trial using a third generation, biodegradable-polymer, everolimus-eluting stent.


Description:

An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive patients presenting with STEMI and MVD in stable hemodynamic conditions, undergoing after successful PCI of the culprit lesion either (1:1 randomization) immediate revascularization of all additional target lesions during the index procedure or staged PCI of all additional target lesions (within 19 to 45 days) using the Boston Scientific Synergy™ stent. The goal of this trial is to compare two treatment strategies that are currently performed in clinical practice: immediate complete revascularization versus staged complete revascularization in patients with STEMI and MVD. Patients randomized to immediate complete revascularization will have treated during the index procedure, after revascularization of the culprit lesion, all significant non-culprit coronary lesions. Patients randomized to staged complete revascularization will have treated during the index procedure only the culprit lesion, and they will be hospitalized after 19-45 days for complete revascularization of all significant non-culprit coronary lesions. For both groups, lesion are considered significant when causing a ≥70% diameter stenosis by visual estimation in at least two projections on the coronary angiogram.


Recruitment information / eligibility

Status Completed
Enrollment 840
Est. completion date May 2023
Est. primary completion date May 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset) - Suitability for PCI from femoral or radial access - Coronary anatomy suitable for complete coronary revascularization with Synergy® stent implantation - Identifiable culprit lesion/artery - At least one non-culprit coronary stenosis = 70% in at least two projections, in a vessel with a lumen diameter =2.25 - =5.75 mm, other than the culprit artery - TIMI Flow 3 or TIMI flow 2 after revascularization of the culprit artery - Stable hemodynamics at the end of the culprit vessel revascularization Exclusion Criteria: - Inability to give informed consent - Cardiogenic shock - Prolonged resuscitation >10 min - General unsuitability for PCI - Need for emergency CABG - Previous CABG - Planned hybrid revascularization - Coronary artery dissection - STEMI due to ST - Previous documented allergic reaction to everolimus or to any stent material - Severe mechanical complication of acute myocardial infarction - Pre-existing severe renal failure (eGFR <30 mL/min) or renal replacement therapy - Chronic total occlusion of a major coronary artery - Left main stem stenosis =50% or left main stem equivalent (ostial left anterior descending and ostial circumflex stenosis =70%) - In-stent restenosis - Panned coronary, cerebrovascular, or peripheral arterial revascularization - Planned cardiac or major surgery - Any contraindications for dual antiplatelet therapy with aspirin and a P2Y12 Inhibitor for at least 90 days, except for patients on oral anticoagulation - Known pregnancy at the time of inclusion - Participation in another clinical study with an investigational product - Life expectancy <1 year

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Staged complete PCI
During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
Immediate complete PCI
During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
Device:
Synergy™ stent
Bioabsorbable Polymer Drug-Eluting Stent

Locations

Country Name City State
Switzerland University Hospital Zürich, Cardiology Department Zurich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

References & Publications (10)

Authors/Task Force members; Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29. No abstract available. — View Citation

Cavender MA, Milford-Beland S, Roe MT, Peterson ED, Weintraub WS, Rao SV. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2009 Aug 15;104(4):507-13. doi: 10.1016/j.amjcard.2009.04.016. Epub 2009 Jun 18. — View Citation

Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L, Jorgensen E, Pedersen F, Saunamaki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aaroe J, Jensen SE, Raungaard B, Kober L; DANAMI-3-PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015 Aug 15;386(9994):665-71. doi: 10.1016/s0140-6736(15)60648-1. — View Citation

Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015 Mar 17;65(10):963-72. doi: 10.1016/j.jacc.2014.12.038. — View Citation

Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, Stone GW; HORIZONS-AMI Trial Investigators. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2011 Aug 9;58(7):704-11. doi: 10.1016/j.jacc.2011.02.071. — View Citation

Sabate M, Raber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iniguez A, Tuller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Juni P, Windecker S. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv. 2014 Jan;7(1):55-63. doi: 10.1016/j.jcin.2013.07.012. Epub 2013 Dec 11. — View Citation

Stahli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, Kesterke R, Nordbeck P, Witzenbichler B, Lang IM, Kessler M, Valina C, Dibra A, Rohla M, Moccetti M, Vercellino M, Gaede L, Bott-Flugel L, Jakob P, Stehli J, Candreva A, Templin C, Schindler — View Citation

Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24. No abstract available. — View Citation

Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG; PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013 Sep 19;369(12):1115-23. doi: 10.1056/NEJMoa1305520. Epub 2013 Sep 1. — View Citation

Widimsky P, Holmes DR Jr. How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease? Eur Heart J. 2011 Feb;32(4):396-403. doi: 10.1093/eurheartj/ehq410. Epub 2010 Nov 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Cost-effectiveness analysis 1 year
Primary The primary outcome measure is a composite of all-cause death, non-fatal myocardial infarction, unplanned ischemia-driven revascularization, hospitalization for heart failure, and stroke at 1 year 1-year
Secondary All-cause death, non-fatal myocardial infarction, unplanned ischemia-driven revascularization, hospitalization for heart failure, and stroke Primary endpoint 6 months
Secondary All-cause death Single components of the primary endpoint 6 months, 1 year
Secondary Non-fatal myocardial infarction Single components of the primary endpoint 6 months, 1 year
Secondary Unplanned ischemia-driven revascularization Single components of the primary endpoint 6 months, 1 year
Secondary Hospitalization for heart failure Single components of the primary endpoint 6 months, 1 year
Secondary Stroke Single components of the primary endpoint 6 months, 1 year
Secondary Target lesion revascularization (TLR) 6 months, 1 year
Secondary Target vessel revascularization (TVR) 6 months, 1 year
Secondary Non-cardiovascular death 6 months, 1 year
Secondary Cardiac death 6 months, 1 year
Secondary Cardiovascular death 6 months, 1 year
Secondary Cardiac death or myocardial infarction 6 months, 1 year
Secondary All-cause death or myocardial infarction 6 months, 1 year
Secondary Stent thrombosis 6 months, 1 year
Secondary Acute renal insufficiency or dialysis 6 months, 1 year
Secondary Procedural success 6 months, 1 year
Secondary Bleeding event (BARC definition) 6 months, 1 year
Secondary Quality of life (EQ-5D questionnaire) 6 months, 1 year
See also
  Status Clinical Trial Phase
Completed NCT01864343 - Target Temperature Management In Myocardial Infarction - A Pilot Study N/A
Completed NCT00962416 - Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI) Phase 4
Active, not recruiting NCT00927615 - Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO) N/A
Recruiting NCT02592694 - Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty Phase 4
Withdrawn NCT01991366 - Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Completed NCT02158468 - Effect of Conditioning on Myocardial Damage in STEMI N/A
Completed NCT01197729 - OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry N/A
Completed NCT06426537 - Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches Early Phase 1
Completed NCT01882179 - Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size Phase 3
Terminated NCT00719914 - A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks Phase 2
Completed NCT00952224 - Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome N/A
Completed NCT00378391 - European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry N/A
Withdrawn NCT04303377 - Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction Phase 2
Completed NCT03523624 - Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
Completed NCT01531114 - PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus Phase 3
Active, not recruiting NCT01960933 - Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization N/A
Completed NCT00502528 - Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction Phase 2
Recruiting NCT02062554 - Brasilia Heart Study
Recruiting NCT04150016 - In-stent Repair and Vessel Reaction of STEMI Patients With OCT N/A
Recruiting NCT03074214 - Prognostic Value of Copeptin for Infarct Size and Prognosis in Patients With ST-elevation Myocardial Infarction N/A